Erdem Göker

Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial

Tony Mok, Yi‐Long Wu, Iveta Kudaba et al. · The Lancet · 2019 · 3.3K citations · Full text

Medicine, Oncology, Pharmacology +15

Afatinib versus erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung (LUX-Lung 8): an open-label randomised controlled phase 3 trial

Jean‐Charles Soria, Enriqueta Felip, Manuel Cobo et al. · The Lancet Oncology · 2015 · 434 citations

Medicine, Oncology, Pharmacology +9

Randomized phase III study comparing irinotecan combined with 5-fluorouracil and folinic acid to cisplatin combined with 5-fluorouracil in chemotherapy naive patients with advanced adenocarcinoma of the stomach or esophagogastric junction

Magdolna Dank, J. Załuski, Carlo Barone et al. · Annals of Oncology · 2008 · 343 citations · Full text

Medicine, Oncology, Pharmacology +13

Arsenic trioxide-mediated cytotoxicity and apoptosis in prostate and ovarian carcinoma cell lines.

Rüçhan Uslu, Canfeza Sezgin, Bülent Karabulut et al. · PubMed · 2000 · 191 citations

Medicine, Oncology, Pharmacology +16

Defective Transport Is a Common Mechanism of Acquired Methotrexate Resistance in Acute Lymphocytic Leukemia and Is Associated With Decreased Reduced Folate Carrier Expression

Richard Görlick, Erdem Göker, Tanya Trippett et al. · Blood · 1997 · 186 citations · Full text

Medicine, Cancer Biology, Pharmacology +15